SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum.
0 ratings in the last 12 months
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.